116 related articles for article (PubMed ID: 7042086)
1. Objective regressions of T- and B-cell lymphomas in patients following treatment with anti-thymocyte globulin.
Fisher RI; Silver BA; Vanhaelen CP; Jaffe ES; Cossman J
Cancer Res; 1982 Jun; 42(6):2465-9. PubMed ID: 7042086
[TBL] [Abstract][Full Text] [Related]
2. B lymphocytes in untreated patients with malignant lymphoma and Hodgkin's disease.
Gajl-Peczalska KJ; Hansen JA; Bloomfield CD; Good RA
J Clin Invest; 1973 Dec; 52(12):3064-73. PubMed ID: 4201499
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
[TBL] [Abstract][Full Text] [Related]
4. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC
J Immunother; 2001; 24(3):263-71. PubMed ID: 11394505
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic expression of non-Hodgkin's lymphomas in China.
Xu LZ; Tu LY; Liu YF; Hsu SM; Qiu BS; Li ZX
J Natl Cancer Inst; 1984 Sep; 73(3):635-8. PubMed ID: 6236322
[TBL] [Abstract][Full Text] [Related]
6. Long-term immunoregulatory effects of therapy with corticosteroids and anti-thymocyte globulin.
Schatz DA; Riley WJ; Silverstein JH; Barrett DJ
Immunopharmacol Immunotoxicol; 1989; 11(2-3):269-87. PubMed ID: 2695566
[TBL] [Abstract][Full Text] [Related]
7. The effect of antithymocyte globulin on anti-human leukocyte antigen antibody detection assays.
Gloor JM; Moore SB; Schneider BA; Degoey SR; Stegall MD
Transplantation; 2007 Jul; 84(2):258-64. PubMed ID: 17667819
[TBL] [Abstract][Full Text] [Related]
8. CD45 monoclonal antibody-mediated cytolysis of human NK and T lymphoma cells.
Wulf GG; Boehnke A; Chapuy B; Glass B; Hemmerlein B; Schroers R; Brenner MK; Truemper L
Haematologica; 2006 Jul; 91(7):886-94. PubMed ID: 16818275
[TBL] [Abstract][Full Text] [Related]
9. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
10. ATG induction therapy: long-term effects on Th1 but not on Th2 responses.
Weimer R; Staak A; Süsal C; Streller S; Yildiz S; Pelzl S; Renner F; Dietrich H; Daniel V; Rainer L; Kamali-Ernst S; Ernst W; Padberg W; Opelz G
Transpl Int; 2005 Feb; 18(2):226-36. PubMed ID: 15691277
[TBL] [Abstract][Full Text] [Related]
11. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
[TBL] [Abstract][Full Text] [Related]
12. Rabbit anti T-lymphocyte globulin induces apoptosis in peripheral blood mononuclear cell compartments and leukemia cells, while hematopoetic stem cells are apoptosis resistant.
Grüllich C; Ziegler C; Finke J
Biol Blood Marrow Transplant; 2009 Feb; 15(2):173-82. PubMed ID: 19167677
[TBL] [Abstract][Full Text] [Related]
13. Induction of in vitro and in vivo antigenic modulation by the anti-human T-cell monoclonal antibody T101.
Shawler DL; Miceli MC; Wormsley SB; Royston I; Dillman RO
Cancer Res; 1984 Dec; 44(12 Pt 1):5921-7. PubMed ID: 6333922
[TBL] [Abstract][Full Text] [Related]
14. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
15. Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone).
Voulgarelis M; Giannouli S; Tzioufas AG; Moutsopoulos HM
Ann Rheum Dis; 2006 Aug; 65(8):1033-7. PubMed ID: 16322082
[TBL] [Abstract][Full Text] [Related]
16. How to differentiate between T-cell-rich B-cell lymphoma and lymphocyte-predominant Hodgkin's disease. Evidence for the value of MB1 and 4KB5 immunostaining.
Schmidt U; Herbst J; Metz KA; Leder LD
J Pathol; 1996 Jun; 179(2):138-44. PubMed ID: 8758204
[TBL] [Abstract][Full Text] [Related]
17. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.
Law CL; Gordon KA; Collier J; Klussman K; McEarchern JA; Cerveny CG; Mixan BJ; Lee WP; Lin Z; Valdez P; Wahl AF; Grewal IS
Cancer Res; 2005 Sep; 65(18):8331-8. PubMed ID: 16166310
[TBL] [Abstract][Full Text] [Related]
18. Rabbit antiserum to human thymocyte membranes: specificity for normal and malignant T-lymphocytes.
Gross N; Bron C
Clin Exp Immunol; 1978 Aug; 33(2):283-91. PubMed ID: 309811
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor effects of anti-T-cell globulin.
Westphal S; Brinkmann H; Kalupa M; Wilke A; Seitz-Merwald I; Penack O
Exp Hematol; 2014 Oct; 42(10):875-82. PubMed ID: 25017629
[TBL] [Abstract][Full Text] [Related]
20. Epstein-barr virus-associated non-Hodgkin's lymphoma of B-cell origin, Hodgkin's disease, acute leukemia, and systemic lupus erythematosus: a serologic and molecular analysis.
Mitarnun W; Pradutkanchana J; Takao S; Saechan V; Suwiwat S; Ishida T
J Med Assoc Thai; 2002 May; 85(5):552-9. PubMed ID: 12188384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
